Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
Clinical Gastroenterology and Hepatology · 2024-10 · 22 (10) · 2096-2106
DOI: 10.1016/j.cgh.2024.02.026 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-10. Verfasst von Laurent Peyrin-Biroulet und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France; INSERM, NGERE, University of Lorraine, Nancy, France; INFINY …. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND & AIMS: Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) and maintenance (U-ENDURE [NCT03345823]) treatment in patients with moderate-to-severe Crohn's disease. Prior biologic failure is often associated with reduced responses to subsequent therapies. This post hoc analysis assessed upadacitinib efficacy by prior biologic failure status. METHODS: Patients were randomized to placebo or upadacitinib 45 mg (UPA45) for 12 weeks (induction). UPA45 clinical responders were enrolled in U-ENDURE and rerandomized to placebo, upadacitinib 15 mg, or upadacitinib 30 mg (UPA30) for 52 weeks. Assessments were by prior biologic failure. RESULTS: Of 1021 patients, 733 (71.8%) had prior biologic failure. Across outcomes and subgroups, upadacitinib-treated patients achieved higher rates vs placebo. During induction, upadacitinib had higher rates vs placebo for clinical remission based on stool frequency/abdominal pain score (without failure: 54.0% vs 28.3%; with failure: 42.2% vs 14.1%) and endoscopic response (without failure: 52.0% vs 16.2%; with failure: 35.7% vs 5.3%). In maintenance, the greatest treatment effect (upadacitinib vs placebo) was among patients with prior biologic failure treated with UPA30 (clinical remission without failure: 58.5% vs 32.7%; with failure: 42.5% vs 8.7%; endoscopic response without failure: 43.9% vs 17.9%; with failure: 38.9% vs 4.0%). Patients without vs with prior biologic failure had fewer adverse events. CONCLUSIONS: Upadacitinib led to higher absolutes rates of clinical and endoscopic outcomes in patients without vs with prior biologic failure. Patients treated with upadacitinib achieved greater rates of clinical and endoscopic improvements vs placebo, regardless of prior biologic exposure. CLINICALTRIALS: gov: NCT03345849, NCT03345836, NCT03345823.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France; INSERM, NGERE, University of Lorraine, Nancy, France; INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France; FHU…
- Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Hepato-Gastroenterology and Digestive Oncology Department, University Hospital CHU of Liège, Liège, Belgium.
- First Department of Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
- Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Förderung
- AbbVie Inc
Zitieren
APA
Peyrin-Biroulet, L., Panaccione, R., Louis, E., Atreya, R., Rubin, D. T., Lindsay, J. O., Siffledeen, J., Lukin, D. J., Wright, J., Watanabe, K., Ford, S., Remple, V. P., Lacerda, A. P., Dubcenco, E., Garrison, A., Zhou, Q., Berg, S., Anyanwu, S. I., & Schreiber, S. (2024). Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure. Clinical Gastroenterology and Hepatology, 22(10), 2096-2106. https://doi.org/10.1016/j.cgh.2024.02.026
Vancouver
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, et al. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure. Clinical Gastroenterology and Hepatology. 2024;22(10):2096-2106. doi:10.1016/j.cgh.2024.02.026
BibTeX
@article{PeyrinBiroulet2024,
author = {Peyrin-Biroulet, Laurent and Panaccione, Remo and Louis, Edouard and Atreya, Raja and Rubin, David T and Lindsay, James O and Siffledeen, Jesse and Lukin, Dana J and Wright, John and Watanabe, Kenji and Ford, Sharanya and Remple, Valencia P and Lacerda, Ana P and Dubcenco, Elena and Garrison, Andrew and Zhou, Qian and Berg, Sofie and Anyanwu, Samuel I and Schreiber, Stefan},
title = {Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {10},
pages = {2096--2106},
doi = {10.1016/j.cgh.2024.02.026}
}
EUVIMED